Evaluation of the Rigicon Infla10® Inflatable Penile Prosthesis (IPP) for Erectile Dysfunction

Recruiting now · Not applicable

Conditions studied: Erectile Dysfunction (ED)

In brief

This study evaluates the long-term safety and effectiveness of the Rigicon Infla10® Inflatable Penile Prosthesis in patients with erectile dysfunction. The study follows patients implanted with the Rigicon Infla10® Pulse™ Dynamic Inflatable Penile Prosthesis for up to 3 years after implantation.

Key facts

Study ID

NCT07273773

Run by

Rigicon, Inc.

People needed

182

Starts

2026-01-26

Expected to finish

2029-07-01

Last updated by the study team

2026-02-27

Who can join

Age: 22 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male ≥22 years of age.
• Diagnosed with erectile dysfunction (impotence).
• Agree to receive Infla10® three-piece IPP as an ED treatment.
• Willing to complete all protocol required for follow-up visits and tests.

You may not qualify if…

• Contraindication to general anesthesia.
• Known allergy or sensitivity to product materials as indicated in the device labeling.
• Previous penile prosthesis or prior enlargement surgeries
• Diagnosed penile sensory neuropathy.
• Patients who are receiving immunosuppressive drugs or have a history of kidney transplantation.
• Patients who are receiving chemotherapy at the time of enrolment.
• Diagnosed with fibrotic disease, such as priapism or Peyronie's disease or Chordee.
• Compromised immune system, such as systemic lupus erythematosus, discoid lupus, or scleroderma.
• Uncontrolled diabetes (HbA1c ≥ 9.0% [≈75 mmol/mol], measured within 90 days prior to surgery.
• Bleeding disorder or coagulopathy that may in the judgment of the investigator preclude safe procedure.
• Active urogenital infection or active skin infection in region of surgery or systemic infection at the time of assessment.
• Clinically significant comorbidities or presence of unstable conditions (e.g. cardiovascular, lung, renal [serum creatinine > 2.0 mg/dl], hepatic, bleeding disorders, or metabolic impairment) that may confound the results of the study or in the judgment of the physician investigator preclude safe procedure.
• Lacking manual dexterity or mental abilities necessary to operate the device.
• Expected life expectancy < two years.
• Unwilling or unable to sign the Informed Consent.
• Unwilling or unable to comply with the follow-up study requirements.
• Psychogenic erectile dysfunction
• Currently participating in an investigational drug or another investigational device exemption (IDE) study.
• The cognitively challenged subjects and subjects with any cognitive disorder that interferes with or precludes direct and accurate communication with the study investigator regarding the study or affects the ability to complete the study questionnaires.
• Incarcerated subjects
• Subjects who are currently using, or who have not previously attempted and failed, standard non-surgical ED therapies including oral or topical treatments.

Where it is running

• Washington Heights Urology — New York, New York, United States (enrolling)
• Atlanta Cosmetic Urology — Atlanta, Georgia, United States (enrolling)
• Perito Urology — Coral Gables, Florida, United States (enrolling)
• Vitality Urology Institute — Houston, Texas, United States
• Kramer Urology — Hyannis, Massachusetts, United States
• UroPartners — Chicago, Illinois, United States
• Urology Partners of North Texas — Arlington, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.